Trial | NCT00446485  Report issue

Title

Efficacy and Safety of Ginkgo Biloba Extract in Mild Cognitive Impairment and Cerebrovascular Insufficiency
Efficacy and Safety of Ginkgo Biloba Standardized Extract (24% Ginkoflavonoglicozides and 6% Terpenes) in Treatment of Mild Cognitive and Concentration Impairment

  • Phase

    Phase 4

  • Study Type

    Interventional

  • Status

    Completed No Results Posted

  • Intervention/Treatment

    yinhsing ...

  • Study Participants

    90
The purpose of the study is to determine weather Ginkgo biloba standardized extract (24% ginkoflavonoglicozides and 6% terpenes) is effective in treatment of cognitive and concentration impairment
Inclusion criteria is cerebrovascular insufficiency MNSE>20. 90 patients are divided into three groups randomly. First group is being administered 120 mg ginkgo biloba extract, second group 60 mg of the extract and the third group has being administered placebo during the period of 6 months. Methods used for evaluation are SCAG, MMSE, MDRS, VFT, CGI, TCD and color Doppler of carotid arteries. Methods used for follow up safety include: routine blood tests, biochemical tests, neurologic and physical examination, vital signs and ECG.
Study Started
May 31
2007
Primary Completion
Apr 30
2010
Study Completion
Apr 30
2010
Last Update
Sep 28
2015
Estimate

Drug Ginkgo biloba standardized extract 24/6

tablets, 120 mg/day (60 mg two times daily) during 6 months

Drug Ginkgo Biloba standardized extract 24/6

tablets, 60 mg/day during 6 months

Drug placebo

placebo during 6 months

1 Active Comparator

Ginkgo Biloba standardized extract 24/6

3 Placebo Comparator

placebo

Criteria 

Inclusion Criteria:

cerebrovascular insufficiency and mild cognitive disorder (MMSE=20-28)

Exclusion Criteria:

pregnancy
cognitive disorder caused by psychological, metabolic endocrine nutritional and heart disorder
alcohol or drug abuse
No Results Posted